Enhancing NEAT to Treat Obesity

加强 NEAT 治疗肥胖

基本信息

  • 批准号:
    8204029
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-04-01 至 2016-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Obesity and overweight affect most Americans as we struggle with the current obesigenic environment. Yet some resist obesity, just as some animals resist obesity. Animal and human studies indicate that spontaneous physical activity (SPA), which generates non-exercise activity thermogenesis (NEAT), is an important defense against weight gain. We have demonstrated that obesity resistant (OR) rats have greater SPA than obesity prone (OP) rats. OP and OR rats, as polygenic strains differing in sensitivity to obesity, are excellent models for polygenic human obesity. Lean humans with elevated SPA resist obesity during caloric challenge, while human obesity is characterized by dramatically reduced SPA, which, by lowering expended energy has a substantial influence on body weight. Brain mechanisms control the level of SPA, and the NEAT so generated. Orexin neurons appear to play a key role as they project to brain areas involved in arousal and activity and loss of brain orexin activity increases body mass index. Sensitivity to orexin A (OxA) SPA promotion is inherent to OR rats and may be critically important in resisting obesity. Recent evidence and our preliminary data suggest that orexin action in the dorsal raphe nucleus (DR) and the locus coeruleus (LC), may mediate SPA and NEAT. We hypothesize that 1) orexin action in DR and LC are key mechanisms mediating SPA and NEAT; 2) viral- mediated overexpression of orexin receptor(s) in obese rodents will reduce body weight; 3) intranasal administration of orexin A, by enhancing orexin levels in brains of rat, will produce enhancement of NEAT. We will test these ideas with three specific aims: Aim 1 will define the role of DR and LC orexin in regulating SPA and NEAT in obesity prone and resistant rats. We will first verify that orexin receptor gene expression in DR and LC is increased in obesity resistant rats (1A); determine sensitivity to DR and LC orexin A infusion in obesity prone and obesity resistant rats (1B), test whether reduced DR or LC orexin receptor function in obesity resistant rats will promote weight gain (1C); determine if orexin A stimulation of DR and LC reduces weight gain in obesity prone rats (1D). In Aim 2 we plan the use of virus-mediated overexpression of orexin receptors in LC or DR to enhance NEAT. Sub-aims will test whether single (2A and 2B) and combined (2C) overexpression of Ox1R and Ox2R in LC or DR of obesity prone rats will reduce weight gain. Finally, in Aim 3 we will perform intranasal (IN) delivery of OxA to determine its effectiveness at increasing NEAT. Sub-aims will determine what effective dose and timing will increase LC and DRN orexin A levels, and whether acute IN (3B) or chronic IN (3C) administration into obese rats increases SPA and NEAT. These studies will fill the gap in knowledge of brain mechanisms underlying SPA, which is important to obesity resistance, and will provide information necessary to developing new obesity therapies for Veterans and the population as a whole. PUBLIC HEALTH RELEVANCE: Biological questions remain about brain mechanisms regulating spontaneous physical activity (SPA), energetic consequences of SPA and the contribution to body weight regulation. Such questions are part of an overall context in which caloric expenditures associated with routine movements are just being defined, and are of great interest to a scientific understanding of the components of energy balance. Overweight and obesity contribute importantly to morbidity associated with many diseases. We believe these studies can begin to address this gap in knowledge. Overweight and obesity is itself a significant disease presence in the veteran population, and contributes significantly to morbidity. Changes in energy balance and particularly the development of obesity exacerbate morbidity of several diseases in veterans. Determining potential avenues for future treatments provides hope in dealing with this national health issue.
描述(由申请人提供): 肥胖和超重影响着大多数美国人,因为我们正在与当前的肥胖环境作斗争。然而,有些人抵制肥胖,就像有些动物抵制肥胖一样。动物和人类研究表明,自发性身体活动(SPA),产生非运动活动产热(NEAT),是防止体重增加的重要防御措施。我们已经证明,肥胖抵抗(OR)大鼠比肥胖倾向(OP)大鼠具有更大的SPA。OP和OR大鼠作为对肥胖敏感性不同的多基因品系,是多基因人类肥胖的良好模型。具有升高的SPA的瘦人在热量挑战期间抵抗肥胖,而人肥胖的特征在于显著降低的SPA,其通过降低消耗的能量对体重具有实质性影响。大脑机制控制SPA的水平,以及由此产生的NEAT。食欲素神经元似乎起着关键作用,因为它们投射到涉及唤醒和活动的大脑区域,并且大脑食欲素活性的丧失增加体重指数。对食欲素A(OxA)SPA促进的敏感性是OR大鼠固有的,并且在抵抗肥胖中可能至关重要。最近的证据和我们的初步数据表明,中缝背核(DR)和蓝斑(LC)中的食欲素作用可能介导SPA和NEAT。我们假设1)在DR和LC中的食欲素作用是介导SPA和NEAT的关键机制; 2)肥胖啮齿动物中病毒介导的食欲素受体的过表达将降低体重; 3)鼻内施用食欲素A,通过增强大鼠脑中的食欲素水平,将产生NEAT的增强。我们将测试这些想法与三个具体的目标:目标1将确定DR和LC食欲素在调节SPA和NEAT在肥胖易感和抵抗大鼠的作用。我们将首先验证在肥胖抵抗大鼠中DR和LC中的食欲素受体基因表达增加(1A);确定在肥胖倾向和肥胖抵抗大鼠中对DR和LC食欲素A输注的敏感性(1B),测试在肥胖抵抗大鼠中降低的DR或LC食欲素受体功能是否会促进体重增加(1C);确定食欲素A刺激DR和LC是否减少肥胖倾向大鼠的体重增加(1D)。在目标2中,我们计划在LC或DR中使用病毒介导的食欲素受体过表达来增强NEAT。子目标将测试在肥胖倾向大鼠的LC或DR中Ox 1 R和Ox 2 R的单一(2A和2B)和组合(2C)过表达是否会减少体重增加。最后,在目标3中,我们将进行OxA的鼻内(IN)递送,以确定其增加NEAT的有效性。子目标将确定什么有效剂量和时间将增加LC和DRN食欲素A水平,以及向肥胖大鼠施用急性IN(3B)或慢性IN(3C)是否增加SPA和NEAT。这些研究将填补对肥胖抵抗很重要的SPA潜在脑机制知识的差距,并将为退伍军人和整个人群开发新的肥胖疗法提供必要的信息。 公共卫生关系: 生物学问题仍然是关于大脑机制调节自发性身体活动(SPA),SPA的能量后果和对体重调节的贡献。这些问题是与日常运动相关的热量消耗刚刚被定义的整体背景的一部分,并且对于科学地理解能量平衡的组成部分非常感兴趣。超重和肥胖是许多疾病发病的重要原因。我们相信这些研究可以开始解决这一知识差距。超重和肥胖本身是退伍军人群体中的一种重要疾病,并显著导致发病率。能量平衡的变化,特别是肥胖的发展加剧了退伍军人中几种疾病的发病率。确定未来治疗的潜在途径为解决这一国家健康问题提供了希望。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Charles J. Billington其他文献

Transcriptome changes correlate with phenotypic severity in Twisted gastrulation mutant mice
  • DOI:
    10.1016/j.ydbio.2009.05.184
  • 发表时间:
    2009-07-15
  • 期刊:
  • 影响因子:
  • 作者:
    Charles J. Billington;Aaron Sarver;Rajaram Gopalakrishnan;Anna Petryk
  • 通讯作者:
    Anna Petryk
Patterns of X-linked inheritance: A new approach for the genome era
  • DOI:
    10.1016/j.gim.2025.101384
  • 发表时间:
    2025-07-01
  • 期刊:
  • 影响因子:
    6.200
  • 作者:
    Sanjana Basava;Charles J. Billington;Laura Carrel;Leslie G. Biesecker;William B. Dobyns
  • 通讯作者:
    William B. Dobyns
PL-42: Vagal blocking for obesity control (VBLOCTM): Ongoing comparison of weight loss with two generations of an active, implantable medical device
  • DOI:
    10.1016/j.soard.2008.03.083
  • 发表时间:
    2008-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    James Toouli;Baard Kulseng;Ulrich Keller;Lilian Kow;Ronald Marvik;Gjermund Johnsen;Daniel M. Frey;Katherine S. Tweden;Richard R. Wilson;Charles J. Billington;Frank G. Moody
  • 通讯作者:
    Frank G. Moody
Artifactual hypoglycemia associated with polycythemia vera.
与真性红细胞增多症相关的人为低血糖。
  • DOI:
    10.1001/jama.1983.03330300058035
  • 发表时间:
    1983
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Charles J. Billington;Dennis A. Casciato;Debra L. Choquette;John E. Morley
  • 通讯作者:
    John E. Morley
P-72: Intermittent vagal blockade with an implantable device improves glycemic control in obese subjects with type 2 diabetes
  • DOI:
    10.1016/j.soard.2009.03.140
  • 发表时间:
    2009-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Miguel F. Herrera;Roy Brancatisano;Ulrich Keller;Baard Kulseng;James Toouli;Anthony Brancatisano;Daniel M. Frey;Lillian Kow;Gjermund Johnsen;Juan P. Pantoja;Deepak Bhole;Robert M. Carey;Katherine S. Tweden;Mark Vollmer;Richard R. Wilson;Charles J. Billington
  • 通讯作者:
    Charles J. Billington

Charles J. Billington的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Charles J. Billington', 18)}}的其他基金

Orexin and serotonin interactions to promote physical activity and prevent obesity
食欲素和血清素相互作用促进身体活动和预防肥胖
  • 批准号:
    10376722
  • 财政年份:
    2017
  • 资助金额:
    --
  • 项目类别:
Orexin and serotonin interactions to promote physical activity and prevent obesity
食欲素和血清素相互作用促进身体活动和预防肥胖
  • 批准号:
    9351676
  • 财政年份:
    2017
  • 资助金额:
    --
  • 项目类别:
Orexin and serotonin interactions to promote physical activity and prevent obesity
食欲素和血清素相互作用促进身体活动和预防肥胖
  • 批准号:
    10045949
  • 财政年份:
    2017
  • 资助金额:
    --
  • 项目类别:
Rescue of dormant brain circuits in neurodegenerative disease
拯救神经退行性疾病中的休眠脑回路
  • 批准号:
    9143208
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
Enhancing NEAT to Treat Obesity
加强 NEAT 治疗肥胖
  • 批准号:
    8431269
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Enhancing NEAT to Treat Obesity
加强 NEAT 治疗肥胖
  • 批准号:
    8838152
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
NEUROPEPTIDE Y--EFFECTS ON ENERGY METABOLISM
神经肽 Y——对能量代谢的影响
  • 批准号:
    6076521
  • 财政年份:
    1999
  • 资助金额:
    --
  • 项目类别:
NEUROPEPTIDE Y--EFFECTS ON ENERGY METABOLISM
神经肽 Y——对能量代谢的影响
  • 批准号:
    2766060
  • 财政年份:
    1998
  • 资助金额:
    --
  • 项目类别:
NEUROPEPTIDE Y--EFFECTS ON ENERGY METABOLISM
神经肽 Y——对能量代谢的影响
  • 批准号:
    2142474
  • 财政年份:
    1996
  • 资助金额:
    --
  • 项目类别:
NEUROPEPTIDE Y--EFFECTS ON ENERGY METABOLISM
神经肽 Y——对能量代谢的影响
  • 批准号:
    2900228
  • 财政年份:
    1991
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了